Interleukin 17 (IL-17) -- a soluble factor thought to promote inflammation and autoimmunity -- can actually suppress the onset of inflammatory bowel disease, shows a paper published online in Nature Immunology.
Previous work documented high concentrations of IL-17 and interferon-gamma, another cytokine implicated in inflammation and autoimmunity, in colon tissue of humans with Crohn's disease and mice with colitis. Using a mouse model of colitis in which immune cells called T cells initiate disease, Richard Flavell and colleagues noted that T cells lacking IL-17 or the IL-17 receptor induced more severe colitis than T cells able to produce and respond to IL-17. IL-17-deficient T cells also released more interferon-gamma. These findings suggest net effects of IL-17 may be pro- or anti-inflammatory, and likely depend on the tissue and environment being examined. Author contact: Richard Flavell (Yale University, New Haven, CT, USA) E-mail: richard.flavell@yale.edu Abstract available online. (C) Nature Immunology press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking
|